Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

483 Reports from FirstWord

   
  • Targeted Therapies in Asthma: Update Bulletin #2 [April 2018]

    ... IIa clinical study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial ... Read More

  • Psoriasis: Update Bulletin #3 [April 2018]

    ... from two pivotal Phase III trials with interleukin-23 (IL-23) inhibitor risankizumab, including head-to-head data with competitor Stelara (ustekinumab; Janssen Biotech); KOL views on the Food and Drug Administration’s (FDA) approval of second-in-class interleukin-23 (IL-23) inhibitor ... Read More

  • Prostate Cancer: Update Bulletin #2 [April 2018]

    ... of Johnson & Johnson’s (J&J’s) next-generation androgen receptor inhibitor Erleada (apalutamide) in patients with non-metastatic castration-resistant prostate cancer (CRPC), data published from the PROSPER study for Pfizer/Astellas’ Xtandi (enzalutamide) in the non-metastatic CRPC population and ... Read More

  • Biosimilars: US Payer Perspectives (2018)

    ... as a solution to stem the tide of soaring drug spending, in the cold light of day, the US biosimilars market has failed to meet expectations. Payers are frustrated. Can the cycle of endless litigation ... Read More

  • Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

    ... of all oral type 2 diabetes mellitus (T2DM) prescriptions in Europe, and certain brands are losing out on market share big time. Is it yours? Find out what’s driving share gains, and what your brand ... Read More

  • CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]

    ... cell therapies in two types of blood cancer. Find out how these novel treatments are impacting treatment choices so far and how their introduction is progressing in the US. Eight of the world’s leading key ... Read More

  • Medical Affairs in Emerging Markets

    ... becoming increasingly complex with developments, such as the increasing use evidence-based prescribing, putting medical affairs (MA) teams under pressure. But in BRIC countries a one size fits all approach to MA will not cater for ... Read More

  • Market Access Impact: Renal Cell Carcinoma (EU5) 2018

    ... cell carcinoma (RCC) prescriptions in Europe, certain brands are losing on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market ... Read More

  • COPD: KOL Insight

    ... the COPD treatment landscape continues to evolve. Of the key companies currently competing in this space -- AstraZeneca, Boehringer Ingelheim, GSK and Novartis -- which companies do key opinion leaders (KOLs) think will take the ... Read More

  • Ovarian Cancer: KOL Insight

    ... How will oncologists choose between AstraZeneca/Merck & Co.’s Lynparza, Tesaro/Merck & Co.’s Zejula and Clovis’ Rubraca which are now all indicated for the maintenance treatment of recurrent tumours and will the role of BRCA mutation ... Read More

  • Market Access Impact: Type 2 Diabetes Mellitus [Orals] (US) 2018

    ... over a third of all oral type 2 diabetes mellitus (T2DM) prescriptions in the US, and certain brands are losing out on market share big time. Is it yours? Find out what’s driving share gains, ... Read More

  • Alzheimer's Disease: Update Bulletin #2 [April 2018]

    ... study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial investigating plasma ... Read More

  • Benchmarking Pharma’s MSL Capabilities

    ... new world. The pharma companies getting the best results from their MSLs have been busy: widening their remit, embracing technology, and fine-tuning structure and focus. What does a forward-thinking MSL team now look like? In ... Read More

  • Benchmarking Key Account Management Capabilities

    ... attributes and operational environment that will deliver optimum performance? What number of brands should a team manage? How much time should they be spending with their key accounts? What level of experience do, on average, ... Read More

  • Renal Cell Carcinoma: Update Bulletin #3 [March 2018]

    ... Phase III IMmotion151 trial of atezolizumab (Tecentriq) in combination with Avastin (bevacizumab) in meeting its co-primary endpoint of investigator-assessed progression-free survival (PFS); AVEO Oncology and EUSA Pharma presenting positive preliminary findings from the Phase II ... Read More

  • Type 2 Diabetes Mellitus: Update Bulletin #2 [March 2018]

    ... recent events in the type 2 diabetes mellitus (T2DM) market, including; the European Commission’s approval of Novo Nordisk’s Ozempic (semaglutide), a once-weekly GLP-1 receptor agonist, for T2DM; The US FDA approval of Merck & Co’s ... Read More

  • Ulcerative Colitis: Update Bulletin #2 [March 2018]

    ... II trial of Otezla (apremilast) in patients with UC; Protalix BioTherapeutics announcing final dosing of the last patient in a Phase II trial evaluating OPRX 106, an oral anti-TNF, in patients with UC; and Pfizer ... Read More

  • Head and Neck Squamous Cell Carcinoma: KOL Insight [2018]

    ... recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and expectations are high that further approvals will continue to improve treatment outcomes. Could locoregional disease become the next frontier in the battle of the immune checkpoint ... Read More

  • Rheumatoid Arthritis: KOL Insight [2018]

    ... however, Eli Lilly/Incyte’s Olumiant (baricitinib) has managed to get first-to-market advantage in Europe. KOL’s weigh in on how Olumiant is faring in the EU, how its availability is impacting Xeljanz, as well as its chances ... Read More

  • Market Access Impact: HIV (US) 2018

    ... HIV prescriptions, the top brand has a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: ... Read More

  • KAM Metrics: Driving efficiency and measuring success

    ... teams operate: the challenge now is to use metrics that reflect the diversity of these sophisticated relationships and drive them forwards. But what works for one contact or KAM may not be appropriate for the ... Read More

  • Multiple Myeloma: Update Bulletin #3 [March 2018]

    ... bluebird bio’s presentation of updated findings from a Phase I trial of their anti-BCMA CAR-T cell therapy bb2121 at ASH 2017;Genmab/Janssen Biotech’s publication of preliminary data from the Phase II CENTAURUS trial, evaluating the safety ... Read More

  • Colorectal Cancer: Update Bulletin #2 [March 2018]

    ... MabVax Therapeutics’ human antibody-based radioimmunotherapy product, MVT-1075; views on the new clinical data presented at the ASCO 2018 Gastrointestinal Cancers Symposium for Taiho Oncology’s Lonsurf (trifluridine and tipiracil); views on new data announced from the ... Read More

  • Atopic Dermatitis: Update Bulletin #2 [March 2018]

    ... of initiation of the global Phase III JADE development program for the Janus Kinase 1 (JAK1) inhibitor, PF 04965842, in patients as young as 12 with moderate to severe AD; AbbVie’s presentation of new positive ... Read More

  • Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

    ... The 150 medical oncologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition? Discover all the ... Read More

2 4 5 6 7 8 9 10

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook